“…3C) piR-23662 (15 fold, p < 0.003), piR-26526 (10 fold, p < 0.00003), piR-26527 (9 fold, p < 0.00009), piR-30293 (9 fold, p < 0.00009) and piR-26528 (8 fold, p < 0.000008) in TNBC compared to normal tissue. Recent studies have also reported the involvement of specific piRNAs in different cancers, for example, piR-4987, piR-20365, piR-20485, piR-20582 and piR-932 in breast cancer 57, 58, piR-823 and piR651 in gastric cancer 59, 60, upregulated piR-32051, piR-39894, piR-43607 and downregulated piR-38756, piR-57125, piR-30924 in kidney cancer 61, piR-Hep1 in liver cancer 62, downregulated piR-017061 in pancreatic cancer 63, downregulated piR-823 in multiple myeloma, downregulated piR-L-163 in lung cancer 64, and piR-59056, piR-32105 and piR-58099 in colon cancer 65. Analyzing stage-wise differential expression of piRNAs, we found 46 piRNAs were shared between stages I & II; three shared piRNAs in stage II & III whereas no common piRNAs in stages I & III.…”